Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
In the management of PNETs it is important to differentiate between functional and nonfunctional PNETs in order to determine the course of treatment.
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
ASCO outlined advances in oncology that were the most clinically meaningful or had the biggest scientific impact from October 2018 through September 2019.
The cancer field is not immune to the challenges of out-of-network and surprise billing.
Pegvorhyaluronidase alfa is an enzyme that breaks down hyaluronan, thought to be a contributor to the structure of the tumor microenvironment in some pancreatic cancers.
Promising results from an earlier-phase study of FOLFOX plus pegilodecakin in metastatic PDAC refractory to gemcitabine provided a rationale for this study.
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
Although higher nurse-to-patient ratios ensure good outcomes for patients undergoing pancreaticoduodenectomy, PD-specific surgeon volume has a greater effect on risks of complications for these patients.
Germline PALB2 pathogenic variants were associated with an increased risk of female or male breast cancer, as well as ovarian and pancreatic cancer.
Results showed that Lynparza had a significantly longer median PFS compared with placebo (7.4 months vs 3.8 months).
Research presented at SITC 2019 looks at 2 different mechanisms for resistance to immune checkpoint inhibition in pancreatic ductal adenocarcinoma.
The chance of missing a disease-causing variant can be as high as 100% across some groups.
During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.